Immunoglobulin treatment in refractory myasthenia gravis

Muscle and Nerve

Volumn 23, Issue 4, 2000, Pages 551-555

  Achiron, Anat ^a   Barak, Yoram ^a   Miron, Shmuel ^a   Sarova Pinhas, Ida ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Immunoglobulins; Myasthenia gravis; Remission; Treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PYRIDOSTIGMINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; DETERIORATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; MALE; MUSCLE FATIGUE; MUSCLE STRENGTH; MYASTHENIA GRAVIS; PRIORITY JOURNAL;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; REMISSION INDUCTION; TIME FACTORS;

EID: 0034110007     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(200004)23:4<551::AID-MUS14>3.0.CO;2-O     Document Type: Article

References (25)

1. Arsura EL, Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 1988;295:438-443.
2. Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gram. Arch Intern Med 1986;146:1365-1368.
3. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Semin Hematol 1988;25:140-158.
4. Brunner NG, Berger CL, Namba T, Grob D. Corticotrpin and corticosteroids in generalized myasthenia gravis: comparative studies and role in management. Ann NY Acad Sci 1976;274: 577-596.
5. Brunner NG, Namba T, Grob D. Corticosteroids in management of severe, generalized myasthenia gravis. Neurology 1972;22:603-610.
6. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases. Muscle Nerve 1999; 22:1479-1497.
7. Devathasan G, Kueh YK, Chong PN. High-dose intravenous gamma globulin for myasthenia gravis. Lancet 1984;II:809-810.
8. Dietrich G, Kazatchkine MD. Normal IgG for therapeutic use contains anti-idiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990;85:620-629.
9. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330: 1797-1810.
10. Fateh-Moghadam A, Wick M, Besinger U, Guersen RG. High-dose intravenous gamma globulin for myasthenia gravis. Lancet 1984;i:848-849.
11. Gajdos PH, Outlin H, Elkharrat D, Brune LD, de Rohan-Chabot P, Raphael JC, Goulon M, Goupon-Goram C, Morel E. High-dose intravenous gamma globulin for myasthenia gravis. Lancet 1984;1:406-407.
12. Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann NY Acad Sci 1981;377:652-669.
13. Hahn AF. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 1998;51(Suppl 5):S16-21.
14. Howard JF. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology 1998;51 (suppl 5): 30-36.
15. Ippoliti G, Cosi V, Piccolo G, Lombardi M, Mantegary R. High-dose intravenous gamma globulin for myasthenia gravis. Lancet 1984;II:809.
16. Kazatchkine MD, Dietrich G, Hurez V, Ronda N, Bellon B, Rossi F, Kaveri SV. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin. Immunol Rev 1994;139:79-107.
17. Keesey J, Buffkin D, Kebo D, Ho W, Herrmann C. Plasma exchange alone as therapy for myasthenia gravis. Ann NY Acad Sci 1981;377:729-743.
18. Lefvert AK. Anti-idiotypic antibodies against the receptor antibodies in myasthenia gravis. Scand J Immunol 1981;13: 493-497.
19. Lefvert AK, Bergstrom K. Acetylcholine receptor antibodies in myasthenia gravis: purification and characterization. Scand J Immunol 1978;8:525-533.
20. Lockwood CM. New treatment strategies for systemic vasculities: the role of intravenous immune globulin therapy. Clin Exp Immunol 1996;104(suppl 1):77-82.
21. Mertens HG, Hertel G, Reuther P, Richer K. Effect of immunosuppressive drugs (azathioprine). Ann NY Acad Sci 1981; 377:691-697.
22. Morell A, Nydegger UE. Clinical use of intravenous immunoglobulins. London: Academic Press: 1986. p 107-111.
23. Olarte MR, Schoenfeldt ES, Penn AS, Lovelace RE, Rowland LP. Effect of plasmapheresis in myasthenia gravis 1978-1980. Ann NT Acad Sci 1981;377:725-728.
24. Oosterhuis HJGH. The natural course of myasthenia gravis: a long-term follow up study. J Neurol Neurosurg Psychiatry 1989; 52:1121-1127.
25. Pascuzzi RM, Coslett HB, Johns TR. Myasthenia gravis treatment with long-term corticosteroids: a report of 116 cases. Ann Neurol 1984;15:291-298.